000			01955 a2200541 4500
005			20250516225509.0
264		0	_c20140902
008			201409s 0 0 rus d
022			_a0869-2092
040			_aNLM _beng _cNLM
100	1		_aKartashova, E A
245	0	0	_a[The influence of citoflavin on molecular mechanisms of hypertensive encephalopathy development in patients with systolic arterial hypertension]. _h[electronic resource]
260			_bEksperimental'naia i klinicheskaia farmakologiia _c2014
300			_a18-23 p. _bdigital
500			_aPublication Type: Journal Article; Randomized Controlled Trial
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAmlodipine _xtherapeutic use
650	0	4	_aAspirin _xtherapeutic use
650	0	4	_aAtorvastatin
650	0	4	_aBlood Pressure _xdrug effects
650	0	4	_aBlood Proteins _xmetabolism
650	0	4	_aDrug Combinations
650	0	4	_aDrug Therapy, Combination
650	0	4	_aEchocardiography
650	0	4	_aFemale
650	0	4	_aFlavin Mononucleotide _xtherapeutic use
650	0	4	_aHemodynamics _xdrug effects
650	0	4	_aHeptanoic Acids _xtherapeutic use
650	0	4	_aHumans
650	0	4	_aHypertension _xblood
650	0	4	_aHypertensive Encephalopathy _xblood
650	0	4	_aInosine Diphosphate _xtherapeutic use
650	0	4	_aMale
650	0	4	_aNeuroprotective Agents _xtherapeutic use
650	0	4	_aNiacinamide _xtherapeutic use
650	0	4	_aPyrroles _xtherapeutic use
650	0	4	_aSignal Transduction _xdrug effects
650	0	4	_aSpectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
650	0	4	_aSuccinates _xtherapeutic use
650	0	4	_aSystole
650	0	4	_aTetrazoles _xtherapeutic use
650	0	4	_aValine _xanalogs & derivatives
650	0	4	_aValsartan
700	1		_aRomantsov, M G
700	1		_aSarvilina, I V
773	0		_tEksperimental'naia i klinicheskaia farmakologiia _gvol. 77 _gno. 6 _gp. 18-23
999			_c24079274 _d24079274